Claims for Patent: 4,851,329

Summary for Patent: 4,851,329

Title:	Immunoassay employing optical pulse particle size analysis
Abstract:	This invention provides a means for determining the concentration of any of a wide range of antibody or antigen molecules with a high degree of specificity, accuracy and sensitivity. Antigen or antibody concentration is determined by effecting an agglutination reaction in a liquid medium and determining the cluster size distribution of agglutinated particles by optical pulse particle size analysis. The measured cluster size distribution then is compared with a standard quantitative relationship between the cluster size distribution and concentration of the antigen or antibody being tested. By this means one may specifically ascertain the absolute concentration of the antigen or antibody in question in the sample being analyzed. In addition to detecting antigen or antibody molecules, the process of this invention can be used to determine the concentration of any substance capable of specifically promoting or inhibiting an agglutination reaction such as viruses, white blood cells or the like.
Inventor(s):	Cohen; Richard J. (Newton Highlands, MA), Broide; Michael L. (Cambridge, MA), Bowen; Mark S. (Medford, MA)
Assignee:	Massachusetts Institute of Technology (Cambridge, MA)
Application Number:	06/871,523
Patent Claims:	1. A method for determining the concentration of a substance which promotes or inhibits an agglutination reaction, comprising: a. determining the quantitative relationship between the cluster size distribution of an agglutinated reaction product and the known concentration of the substance being tested using a fixed concentration of an agglutinant wherein the cluster size distribution of the agglutinated reaction product is measured by optical pulse particle size analysis; b. mixing an unknown concentration of one or more dilutions of the substance being tested with the same agglutinant to form at least one agglutinated reaction product of the dilutions; c. determining the cluster size distribution of the agglutinated reaction product of the dilutions by the optical pulse particle size analysis; and d. comparing the cluster size distribution obtained in step (c) with the quantitative relationship determined by size (a) to determine the concentration of the substance. 2. A method of claim 1, wherein the substance being tested is an antigen which is combined with a fixed amount of its complementary antibody. 3. A method of claim 1, wherein the substance being tested is an antibody which is combined with a fixed amount of its complementary antigen. 4. A method of claim 1, wherein the substance being tested is a virus and the agglutinant comprises red blood cells. 5. A method of claim 1, wherein the substance being tested comprises an antibody to a virus and wherein the agglutinated reaction products are obtained by mixing said antibody with a fixed concentration of said virus to inactivate said antibody and adding a fixed concentration of red blood cells to said mixture to effect an agglutination reaction of said virus and said blood cells. 6. A method of claim 1, wherein lymphocyte cells obtained from one individual are used to agglutinate the substance being tested which comprises lymphocyte cells obtained from a second individual. 7. A method of claim 1, wherein the cluster size distribution is determined by measuring the concentration or numbers of carrier particle dimers. 8. A method of claim 1, wherein the cluster size distribution is determined by measuring the ratio of the number of carrier particle dimers to the number of carrier particle monomers. 9. A method of claim 1, wherein the agglutinant comprises antigen-coated carrier particles and the substance being tested is a complementary antibody. 10. A method of claim 9, wherein the substance being tested is an antibody against a virus, a bacterium, a pharmacologic agent, a tumor associated antigen, a transplantation antigen, or an antibody associated with autoimmunity. 11. A method of claim 9 wherein the carrier particle is a polystyrene or latex microsphere. 12. A method of claim 9, wherein the carrier particle is a red blood cell or a lymphocyte. 13. A method of claim 1, wherein the agglutinant comprises antibody-coated carrier particles and the substance being tested for is a complementary antigen. 14. A method of claim 13, wherein the antigen is a hormone, a polyhaptenic drug, a bacterial or viral antigen or a tumor associated antigen. 15. A method of claim 13, wherein the antigen is insulin, parathyroid hormone, luteinizing hormone, digoxin, a barbituate, morphine, diphenylhydantoin, theophylline, an antibiotic, HTLV-III antigen, hepatitis antigen or carcinoembryonic antigen. 16. A method of claim 13, wherein the carrier particle is a polystyrene or latex microsphere. 17. A method of claim 13, wherein the carrier particle is a red blood cell or a lymphocyte. 18. A method of claim 1, wherein the substance being tested in an antigen which first is mixed with a fixed concentration of its complementary antibody and the resultant mixture combined with a fixed concentration of said antigen coated on carrier particles. 19. A method of claim 18, wherein the antigen is a hormone, a mono- or polyhaptenic drug, a bacterial or viral antigen or a tumor associated antigen. 20. A method of claim 18, wherein the antigen is insulin, parathyroid hormone, luteinizing hormone, digoxin, a barbituate, morphine, diphenylhydantoin, theophylline, an antibiotic, HTLV-III antigen, hepatitis antigen or carcinoembryonic antigen. 21. A method of claim 18, wherein the carrier particle is a polystyrene or latex microscope. 22. A method of claim 18, wherein the carrier particle is a red blood cell or a lymphocyte. 23. A method of claim 1, wherein the substance being tested is an antibody which first is mixed with a fixed concentration of its complementary antigen and the resultant mixture combined with a fixed concentration of the antibody coated on carrier particles. 24. A method of claim 23, wherein the substance being tested is an antibody against a virus, a bacterium, a pharmacologic agent, a tumor associated antigen, a transplantation antigen, or an antibody associated with auto-immunity.

Details for Patent 4,851,329

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2039-02-26